Tregs also have blunted proliferation and reduced cell-cycle progression during the early stages of MDS, accompanied by a heightened expansion of IL-17 and GM-CSF secreting Th17 cells in the marrow of low-risk MDS patients (138). The gene discussed is CSF2; the disease is myelodysplastic syndrome.